Skip to main content
. 2017 Mar 30;50(1):175–182. doi: 10.4143/crt.2016.535

Fig. 1.

Fig. 1.

Kaplan-Meier estimates of progression-free survival (PFS) in patients treated with gemcitabine and docetaxel combination as a second or subsequent line treatment in Korea. CI, confidence interval.